Core Viewpoint - NVE Corporation's shares have experienced a 1.5% decline following the release of its second-quarter fiscal 2026 results, despite a 9.7% increase over the past month, indicating investor optimism about future growth prospects despite current revenue challenges [1] Earnings & Revenue Performance - Total revenues for the quarter ended September 30, 2025, were $6.35 million, a 6% decrease from $6.76 million in the prior year, primarily due to a 68% drop in contract R&D revenues, partially offset by a 1% increase in product sales [2] - For the first half of fiscal 2026, total revenues decreased 8% year over year to $12.45 million, with net income down 15% to $6.89 million, or $1.42 per diluted share [3] Operating Trends & Other Key Business Metrics - Gross profit for the quarter declined 14% to $4.97 million, resulting in a gross margin of 78%, down from 86% the previous year due to a less profitable product mix and increased distributor sales [4] - Operating expenses fell 7%, driven by a 23% decrease in SG&A costs, while R&D spending rose by 3% [5] Management Commentary - The CEO highlighted a 4% sequential revenue increase driven by strong growth in distributor and non-defense sales, despite a decline in defense-related business [7] - The company is shifting focus towards medical devices, industrial automation, and robotics markets, leveraging its spintronic sensors and couplers [8] Factors Influencing Performance - Revenue decline was mainly due to cyclical weakness in contract R&D, with a 21% rise in non-defense product sales partially offsetting a 64% decline in defense sales [11] - The lower gross margin was attributed to a shift in sales mix and a 45% year-over-year increase in the cost of sales due to heightened manufacturing activity [12] Outlook - Management is optimistic about continued growth in the December quarter and the second half of fiscal 2026, citing a healthy sales pipeline and favorable tax credits [14] - The company plans to spend an additional $1-$1.5 million on capital expenditures for production expansion [14] Other Developments - The board declared a quarterly cash dividend of $1 per share, payable on November 28, 2025, and reported the completion of new manufacturing equipment installation [16]

Financial Data and Key Metrics Changes - Revenue increased by 4% sequentially but decreased by 6% year-over-year, primarily due to a 68% decrease in contract R&D revenue, partially offset by a 1% increase in product sales [3][7] - Gross margin decreased to 78% from 86% year-over-year due to a less profitable product mix and strong distributor sales [4] - Net income for the quarter was $3.31 million or $0.68 per diluted share, down from $4.03 million or $0.83 per share in the prior year quarter [7] - Operating margin was 58%, pre-tax margin was 65%, and net margin was 52% [7] Business Line Data and Key Metrics Changes - Contract R&D revenue constituted 3% of total revenue, with a significant year-over-year decrease attributed to defense-related projects [3] - Non-defense sales increased by 21%, while defense sales decreased by 64%, reflecting volatility in defense procurement cycles [3][4] - Distributor sales showed strong growth both sequentially and year-over-year, contributing positively to overall revenue [4] Market Data and Key Metrics Changes - The defense business, while not part of the growth strategy, has been recovering steadily this fiscal year, with sequential increases in sales [3] - The company reported strong growth in the medical device market, highlighting new products aimed at this sector [13] Company Strategy and Development Direction - The company aims to develop advanced products and enhance capabilities through new equipment, focusing on high-value markets such as medical devices and robotics [10][11] - The R&D strategy emphasizes creating the best electronics for high-value applications, including electric vehicles and advanced robotics [10] - The company is targeting growth in non-defense markets while maintaining a presence in defense-related projects for intellectual property development [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a strong pipeline in most business areas and a recovering industry [52] - The company anticipates a full-year tax rate of 16% to 17%, benefiting from advanced manufacturing investment tax credits [6] - Management acknowledged the potential for significant revenue from defense contracts but emphasized a focus on faster-growing markets [57][60] Other Important Information - The company launched three new products in the past quarter, including a rotation sensor and a wafer-level chip-scale voltage regulator [11] - The installation of new production equipment is expected to enhance capacity and capabilities, allowing for in-house wafer-level chip-scale packaging [10] Q&A Session Summary Question: Will the new equipment lead to revenue growth or just increased capabilities? - Management indicated that the goal is to develop advanced products and fuel future growth, implying both revenue growth and enhanced capabilities [16] Question: When should growth be expected from the new products? - Management expects growth to begin as soon as the current quarter, particularly in industrial markets [17] Question: Is there a fully domestic supply chain for the new parts? - The company has a mostly domestic supply chain, with key operations conducted in-house, reducing susceptibility to supply chain risks [20] Question: What role do the company's products play in medical devices? - The company provides secure communication solutions for medical devices, emphasizing small size, low power, and reliability [23] Question: How does the company approach contract R&D? - Contract R&D is viewed as a means to build intellectual property and facilitate future sales, primarily in defense-related projects [48][49] Question: What is the outlook for the defense market? - While the defense market is not seen as a long-term growth engine, the company actively seeks large contracts and opportunities within this sector [57][60]

Financial Data and Key Metrics Changes - Revenue increased by 4% sequentially but decreased by 6% year-over-year, primarily due to a 68% decrease in contract R&D revenue, partially offset by a 1% increase in product sales [3][7] - Gross margin decreased to 78% from 86% year-over-year due to a less profitable product mix and strong distributor sales [4] - Net income for the quarter was $3.31 million or $0.68 per diluted share, down from $4.03 million or $0.83 per share in the prior year quarter [7] - Operating margin was 58%, pre-tax margin was 65%, and net margin was 52% [7] Business Line Data and Key Metrics Changes - Non-defense sales increased by 21%, while defense sales decreased by 64%, with defense product sales accounting for 8% of revenue [3][4] - Contract R&D revenue constituted 3% of total revenue, primarily related to defense or government contracts [3] Market Data and Key Metrics Changes - Distributor sales increased both sequentially and year-over-year, indicating a recovery in this segment [4][46] - The defense business has been steadily recovering this fiscal year, with sequential increases in sales [3] Company Strategy and Development Direction - The company aims to develop advanced products and fuel future growth through new equipment and R&D, focusing on high-value markets such as medical devices and robotics [10][11] - The strategy includes launching new products that enhance capabilities and address market needs, such as a rotation sensor and a wafer-level chip-scale voltage regulator [11] - The company is targeting growth in the industrial Internet of Things and artificial intelligence of things, viewing these as significant opportunities [61] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a strong pipeline and recovery in the industry [53] - The company anticipates a full-year tax rate of between 16% and 17%, benefiting from advanced manufacturing investment tax credits [6] - Management acknowledged the volatility in contract R&D but emphasized its role in building intellectual property and facilitating future sales [49][58] Other Important Information - The company successfully installed new production equipment, which is expected to enhance capacity and capabilities [9][10] - The tax law changes will reduce cash taxes by approximately $1 million over three quarters, starting this quarter [6][7] Q&A Session Summary Question: Will the new equipment lead to revenue growth or just increased capabilities? - The company aims for both increased capabilities and new product development to drive future growth [16] Question: When should growth from chip-scale packaging be expected? - Growth is anticipated as soon as the current quarter, particularly in industrial markets [17] Question: Is there a fully domestic supply chain for the new parts? - The company has a mostly domestic supply chain, with key operations conducted in-house [21] Question: What functions do the company’s products serve in hearing aids and medical devices? - The products enable secure communications for data transfer, emphasizing small size, low power, and reliability [24] Question: How does the company approach contract R&D? - Contract R&D is viewed as a way to build intellectual property and facilitate future sales, primarily in defense [49][58] Question: Is the defense market a target for the company? - While the defense market is not seen as a long-term growth engine, the company does seek revenues and large contracts in this area [58][61]

Financial Data and Key Metrics Changes - Revenue increased by 4% sequentially but decreased by 6% year-over-year, primarily due to a 68% decrease in contract R&D revenue, partially offset by a 1% increase in product sales [3][6] - Net income for the second quarter was $3.31 million or $0.68 per diluted share, down from $4.03 million or $0.83 per share in the prior year quarter, attributed to decreased revenue, lower margins, and a higher tax rate [7][6] - Gross margin decreased to 78% from 86% in the prior year quarter due to a less profitable product mix and strong distributor sales [4] Business Line Data and Key Metrics Changes - Non-defense sales increased by 21%, while defense sales decreased by 64%, with defense product sales accounting for 8% of revenue [3][6] - Contract R&D revenue constituted 3% of total revenue, primarily related to defense or government contracts [3] Market Data and Key Metrics Changes - Distributor sales increased both sequentially and year-over-year, indicating a recovery in this segment [4][3] - The defense business has been steadily recovering this fiscal year, with sequential increases in defense industry sales noted [3] Company Strategy and Development Direction - The company aims to develop advanced products and fuel future growth through new equipment and R&D, focusing on high-value markets such as medical devices and autonomous vehicles [10][11] - The strategy includes launching new products that enhance capabilities and address market needs, such as a rotation sensor and a wafer-level chip-scale voltage regulator [11][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a strong pipeline and recovery in the industry, particularly in non-defense sales [90][97] - The company anticipates a full-year tax rate of between 16% and 17%, benefiting from advanced manufacturing investment tax credits [5] Other Important Information - The company successfully installed new production equipment, which is expected to enhance capacity and capabilities, allowing for in-house wafer-level chip-scale packaging [10][9] - The company participated in the Medical Design and Manufacturing Trade Show, showcasing new products and generating leads for future sales [12][13] Q&A Session Summary Question: Will the new equipment lead to revenue growth or just increased capabilities? - The company aims to use the new equipment to develop advanced products and fuel future growth, indicating both revenue growth and enhanced capabilities [17] Question: When should growth be expected from the new equipment? - Management indicated that growth could be seen as soon as the current quarter, particularly in core markets [21][22] Question: Is there a fully domestic supply chain for the new parts? - The company has a mostly domestic supply chain, with key operations conducted in-house, including wafer deposition and testing [29][30] Question: What role does contract R&D play in the company's strategy? - Contract R&D is viewed as a way to facilitate future sales and build intellectual property, primarily in defense-related projects [84][97] Question: How does the company view the defense market? - While the defense market is not seen as a long-term growth engine, the company does seek revenues from large contracts and considers it an important part of the business [97][100]